Other
LINFU®
LINFU® is an intervention with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DIAGNOSTIC TEST
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)
Highest Phase Reached
UnknownTrial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Not yet recruiting1
Enrolling by invitation1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
N/A
Trials by Phase
N/A1 (100.0%)
Trials by Status
not_yet_recruiting133%
enrolling_by_invitation133%
completed133%
Recent Activity
0 active trials
Showing 3 of 3
enrolling_by_invitation
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
NCT06276764
not_yet_recruiting
The LINFU® U.S. Registry for the in the General Population Without Risk Factors
NCT06276803
completednot_applicable
A Proof-of-Concept Study Evaluating LINFU™
NCT05161013
Clinical Trials (3)
Showing 3 of 3 trials
NCT06276764
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
NCT06276803
The LINFU® U.S. Registry for the in the General Population Without Risk Factors
NCT05161013Not Applicable
A Proof-of-Concept Study Evaluating LINFU™
All 3 trials loaded
Drug Details
- Intervention Type
- DIAGNOSTIC TEST
- Total Trials
- 3